Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Renal Failure
  Free Subscription

Articles published in
Kidney Int
    November 2025
  1. HUGHES A, Gonzalez AM, van Zwieten A, Guha C, et al
    Establishing a core outcome measure for life participation in children with chronic kidney disease: a Standardised Outcomes in Nephrology - children and adolescents with chronic kidney disease (SONG-Kids) consensus workshop report.
    Kidney Int. 2025 Nov 25:S0085-2538(25)00887-7. doi: 10.1016/j.kint.2025.
    >> Share

  2. CHRYSOSTOMOU C, Faustini F, Segelmark M, Carrero JJ, et al
    A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.
    Kidney Int. 2025 Nov 21:S0085-2538(25)00883-X. doi: 10.1016/j.kint.2025.
    >> Share

  3. TANGRI N, Neuen BL, Cherney DZ, Tuttle KR, et al
    From Progression to Remission: A New Paradigm for Success in Chronic Kidney Disease.
    Kidney Int. 2025 Nov 6:S0085-2538(25)00847-6. doi: 10.1016/j.kint.2025.
    >> Share

  4. SHUE I, Cherian R, Walker X, Slater K, et al
    The Case | Refractory hyperkalemia after ileostomy in a hemodialysis patient.
    Kidney Int. 2025;108:955-956.
    >> Share

  5. COZZI E
    Delisting of HLA antigens as a possible strategy to enable transplantation in highly sensitized patients with a cPRA >/= 99.9.
    Kidney Int. 2025;108:748-751.
    >> Share

    October 2025
  6. SHROFF R, Schaefer F
    Optimizing cardiovascular outcomes in pediatric dialysis.
    Kidney Int. 2025 Oct 25:S0085-2538(25)00840-3. doi: 10.1016/j.kint.2025.
    >> Share

  7. FURTH SL, Colhoun HM, Kanbay M, Kukla A, et al
    The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Oct 9:S0085-2538(25)00774-4. doi: 10.1016/j.kint.2025.
    >> Share

  8. HARTZ W, Kinniry P
    Hypertriglyceridemia causing dialysis filter lipid deposition.
    Kidney Int. 2025;108:718.
    >> Share

  9. RAVI KS, Mc Causland FR
    Where next for potassium binders in hemodialysis?
    Kidney Int. 2025;108:534-536.
    >> Share

  10. WONG G, Teixeira-Pinto A
    Redefining kidney failure: broadening metrics to realize equity in kidney care.
    Kidney Int. 2025;108:532-533.
    >> Share

    September 2025
  11. SMOYER WE, Gillespie BS, Oni L, Nester C, et al
    STRATEGIES FOR THE DEVELOPMENT OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS FOR KIDNEY PROTECTION IN PEDIATRIC CHRONIC KIDNEY DISEASE: PROCEEDINGS OF A WORKSHOP MEETING IN JULY 2023.
    Kidney Int. 2025 Sep 24:S0085-2538(25)00747-1. doi: 10.1016/j.kint.2025.
    >> Share

  12. CIROVIC A, Cirovic A
    Beyond fibroblast growth factor 23-fibroblast growth factor receptor 4: could aldosterone-driven iron deficiency impact cardiac remodeling in chronic kidney disease?
    Kidney Int. 2025;108:499.
    >> Share

    August 2025
  13. ITO H, Sato T, Sato F, Taniguchi Y, et al
    The Case | Acute neck swelling in a patient undergoing dialysis.
    Kidney Int. 2025;108:335-336.
    >> Share

  14. PIRBUCCUS M, Dufour I, Akachar Y, Goffin E, et al
    "Strawberry milkshake" effluent in a patient undergoing peritoneal dialysis.
    Kidney Int. 2025;108:331.
    >> Share

  15. PICCOLI GB, Orozco A, Shemies R, Attini R, et al
    Postpartum counseling and interventions to reduce the risk of chronic kidney disease: back to the future.
    Kidney Int. 2025;108:160-166.
    >> Share

    July 2025
  16. MURAKAMI N, Blosser CD, Webber AB, Gupta G, et al
    Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.
    Kidney Int. 2025 Jul 28:S0085-2538(25)00576-9. doi: 10.1016/j.kint.2025.
    >> Share

  17. FISHBANE S, Dember LM, Jadoul M, Kovesdy CP, et al
    The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.
    Kidney Int. 2025 Jul 4:S0085-2538(25)00509-5. doi: 10.1016/j.kint.2025.
    >> Share

  18. TEMPLE K, Lester R, Sinclair N, Owen K, et al
    Indigenous spirituality and cultural knowledges provide strength and resilience to Aboriginal people with chronic kidney disease.
    Kidney Int. 2025;108:2-4.
    >> Share

  19. AGARWAL R
    Steroidal or nonsteroidal mineralocorticoid receptor antagonists for reducing cardiovascular burden in chronic kidney disease.
    Kidney Int. 2025;108:11-14.
    >> Share

    June 2025
  20. RAILLON LA, Florens N, Payelle F, Martin M, et al
    Medium chain fatty acids are potent binding competitors to improve protein-bound uremic toxin clearance during hemodialysis.
    Kidney Int. 2025 Jun 25:S0085-2538(25)00492-2. doi: 10.1016/j.kint.2025.
    >> Share

  21. ORTIZ A, Arreola Guerra JM, Chan JCN, Jha V, et al
    Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00334-5. doi: 10.1016/j.kint.2025.
    >> Share

  22. CUCCHIARI D, Mancebo-Sierra E, Caro JL, Meneghini M, et al
    A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody >/= 99.9.
    Kidney Int. 2025 Jun 6:S0085-2538(25)00427-2. doi: 10.1016/j.kint.2025.
    >> Share

  23. RIZZOLO K, Villegas L, Cervantes L
    The national landscape of kidney transplantation for undocumented immigrants: advancing kidney transplantation equity.
    Kidney Int. 2025;107:976-979.
    >> Share

  24. CHARYTAN DM, Winkelmayer WC, Granger CB, Middleton JP, et al
    Corrigendum to "Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients
    Kidney Int. 2025;107:1123.
    >> Share

    May 2025
  25. MITROFANOVA A, Fontanella AM, Molina J, Zhang G, et al
    The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome.
    Kidney Int. 2025 May 30:S0085-2538(25)00407-7. doi: 10.1016/j.kint.2025.
    >> Share

  26. MUREA M, Torreggiani M, Deira J, Sirich TL, et al
    From Niche to Norm: A Multi-Action Plan to Close Gaps and Mainstream Incremental Hemodialysis.
    Kidney Int. 2025 May 20:S0085-2538(25)00404-1. doi: 10.1016/j.kint.2025.
    >> Share

  27. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.
    Kidney Int. 2025;107:767-771.
    >> Share

    April 2025
  28. LI F, Lan Q, Wang Y, Xiong J, et al
    Single-cell analysis of proximal tubular cells with different DNA content reveals functional heterogeneity in the acute kidney injury to chronic kidney disease transition.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00332-1. doi: 10.1016/j.kint.2025.
    >> Share

  29. ERICKSON KF, Fotheringham J
    Is online hemodiafiltration a cost-effective alternative to conventional hemodialysis?
    Kidney Int. 2025;107:602-605.
    >> Share

    March 2025
  30. STACK AG
    Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
    Kidney Int. 2025;107:394-396.
    >> Share

  31. JENSEN M, Jensen BL
    Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease.
    Kidney Int. 2025;107:391-394.
    >> Share

    February 2025
  32. BONNIN-MARQUEZ A, Jankowski J, Maas SL, Hermann J, et al
    Guanidinylation compromises the anti-inflammatory and anti-oxidative properties of apolipoprotein A-I in chronic kidney disease progression.
    Kidney Int. 2025 Feb 24:S0085-2538(25)00171-1. doi: 10.1016/j.kint.2025.
    >> Share

  33. ZHU D, Judge PK, Wanner C, Haynes R, et al
    THE PREVENTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH METABOLIC SYNDROME.
    Kidney Int. 2025 Feb 20:S0085-2538(25)00141-3. doi: 10.1016/j.kint.2024.
    >> Share

  34. MENON G, Metoyer GT, Li Y, Chen Y, et al
    A national registry study evaluated the landscape of kidney transplantation among presumed unauthorized immigrants in the United States.
    Kidney Int. 2025 Feb 14:S0085-2538(25)00088-2. doi: 10.1016/j.kint.2025.
    >> Share

  35. FUCHS MAA, Burke EJ, Latic N, Murray S, et al
    Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
    Kidney Int. 2025 Feb 7:S0085-2538(25)00087-0. doi: 10.1016/j.kint.2025.
    >> Share

  36. HSU SN, Stephen LA, Phadwal K, Dillon S, et al
    Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00085-7. doi: 10.1016/j.kint.2025.
    >> Share

  37. HUGHES A, Scholes-Robertson N, Coghlan D, Wu R, et al
    Identifying strategies for disseminating research to patients with chronic kidney disease and caregivers: a workshop report.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00083-3. doi: 10.1016/j.kint.2025.
    >> Share

    January 2025
  38. SCHOUTEN AEM, Fischer F, Blankestijn PJ, Vernooij RWM, et al
    A health economic evaluation of the multinational, randomized controlled CONVINCE trial - cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis.
    Kidney Int. 2025 Jan 21:S0085-2538(25)00068-7. doi: 10.1016/j.kint.2024.
    >> Share

  39. KETTELER M, Evenepoel P, Holden RM, Isakova T, et al
    Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jan 10:S0085-2538(24)00810-X. doi: 10.1016/j.kint.2024.
    >> Share

  40. HOLE B, Coast J, Caskey FJ, Selman LE, et al
    A choice experiment of older patients' preferences for kidney failure treatments.
    Kidney Int. 2025;107:130-142.
    >> Share

  41. WATANABE S, Sawa N, Hiramatsu R, Oba Y, et al
    The Case | A patient with chronic kidney disease and new-onset heart failure.
    Kidney Int. 2025;107:195-196.
    >> Share

    December 2024
  42. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    >> Share

  43. HANOUNEH M, Stewart S, Aktay R, Fang AS, et al
    Chylothorax and chylopericardium in a dialysis patient.
    Kidney Int. 2024;106:1190.
    >> Share

  44. BOBOT M, Burtey S
    New insights into mechanisms underlying cognitive impairment in chronic kidney disease.
    Kidney Int. 2024;106:1020-1022.
    >> Share

    November 2024
  45. AMINI M, Frisch J, Jost P, Sarakpi T, et al
    Purinergic receptor P2X7 regulates interleukin-1alpha mediated inflammation in chronic kidney disease in a reactive oxygen species-dependent manner.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00798-1. doi: 10.1016/j.kint.2024.
    >> Share

  46. VAN DEN BERG CW, Dumas SJ, Little MH, Rabelink TJ, et al
    Challenges in maturation and integration of kidney organoids for stem cell-based renal replacement therapy.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00806-8. doi: 10.1016/j.kint.2024.
    >> Share

  47. KO TY, Wu CC, Hsieh MY, Yang CW, et al
    A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00792-0. doi: 10.1016/j.kint.2024.
    >> Share

  48. GHANG B, Park J, Lee JS, Lim JS, et al
    Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00789-0. doi: 10.1016/j.kint.2024.
    >> Share

  49. GEORGERY H, Lengele JP, Leflot S, Gillion V, et al
    Recurrent iodine-induced sialadenitis in a patient undergoing hemodialysis: is this really ineluctable?
    Kidney Int. 2024;106:997.
    >> Share

  50. HAMDAN H, Roshanravan B
    Dialysis modality and quality of life: more answers yet more questions.
    Kidney Int. 2024;106:792-794.
    >> Share

  51. SHAREEF Z, Spradling M, Blair P, Quinones-Vargas I, et al
    Appendicitis associated with sevelamer use in a patient receiving peritoneal dialysis.
    Kidney Int. 2024;106:1000.
    >> Share

  52. YANAGI T, Kikuchi H, Takeuchi K, Susa K, et al
    ULK1-regulated AMP sensing by AMPK and its application for the treatment of chronic kidney disease.
    Kidney Int. 2024;106:887-906.
    >> Share

    October 2024
  53. IKIZLER TA, Drueke TB, Floege J, Wong G, et al
    Avoiding Arrythmias by Personalizing Dialysate Concentration: A Case for Precision Medicine in Dialysis Patients.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00721-X. doi: 10.1016/j.kint.2024.
    >> Share

  54. CHARYTAN DM, Winkelmayer WC, Granger CB, Middleton JP, et al
    Effects of dialysate potassium concentration of 3.0mEq/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0mEq/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00722-1. doi: 10.1016/j.kint.2024.
    >> Share

  55. BAJAJ A, Arora M, Bhatt U
    The Case | Dark dialysate after colonoscopy.
    Kidney Int. 2024;106:761-762.
    >> Share

  56. SHARMA Y, Tiwari V, Tyagi V, Bhargava V, et al
    CAPD catheter obstruction by fallopian tubes.
    Kidney Int. 2024;106:760.
    >> Share

  57. CHEN WLJ, Fung KFK, Chan EY
    Nephronophthisis-associated ciliopathy with brachydactyly, medullary cysts, and chronic kidney disease.
    Kidney Int. 2024;106:759.
    >> Share

    September 2024
  58. BISHOP NC
    Unpicking the multi-omic response to endurance training: relevance for exercise benefits in chronic kidney disease.
    Kidney Int. 2024 Sep 18:S0085-2538(24)00646-X. doi: 10.1016/j.kint.2024.
    >> Share

  59. TONG KC, Wee KW
    Cardiovascular disease as a risk factor for frailty in dialysis patients.
    Kidney Int. 2024;106:537-538.
    >> Share

  60. GARG AX, Young A
    Improving the management of chronic kidney disease in primary care by enhancing laboratory reports with additional information and follow-up procedures.
    Kidney Int. 2024;106:366-368.
    >> Share

    August 2024
  61. BERGERON NAD, Candellier A, Rousseau-Gagnon M, Mac-Way F, et al
    Unusual cause of retroperitoneal leak in a patient undergoing peritoneal dialysis.
    Kidney Int. 2024;106:321.
    >> Share

  62. TOUSSAINT ND, Badve SV
    Normalizing serum phosphate based on association, not causation? Lessons in dialysis should have taught us not to fix what we can't prove is broken.
    Kidney Int. 2024;106:195-199.
    >> Share

  63. HAMANO T, Fukagawa M
    Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis.
    Kidney Int. 2024;106:191-195.
    >> Share

    July 2024
  64. ROSE M, Fischer FH, Liegl G, Strippoli GF, et al
    The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00534-9. doi: 10.1016/j.kint.2024.
    >> Share

  65. ZIMMERMANN S, Mathew A, Bondareva O, Elwakiel A, et al
    Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00535-0. doi: 10.1016/j.kint.2024.
    >> Share

  66. JOHNSON RJ, Mandell BF, Schlessinger N, Mount DB, et al
    Controversies and practical management of patients with gout and chronic kidney disease.
    Kidney Int. 2024 Jul 19:S0085-2538(24)00473-3. doi: 10.1016/j.kint.2024.
    >> Share

  67. STAMELLOU E, Noels H, Floege J
    Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
    Kidney Int. 2024;106:21-23.
    >> Share

  68. SAHINOZ M, Ikizler TA
    Inflammasome activation: unraveling the link between chronic kidney disease and atrial fibrillation.
    Kidney Int. 2024;106:6-9.
    >> Share

  69. MEDINA RANGEL PX, Ishibe S
    Preventing MMP23-mediated cleavage of podocyte RARRES1: a novel strategy to halt chronic kidney disease progression?
    Kidney Int. 2024;106:16-18.
    >> Share

  70. WONG G, Guha C, Mallitt KA, van Zwieten A, et al
    The randomized controlled trial (NAVKIDS2) of a patient navigator program created for children with chronic kidney disease.
    Kidney Int. 2024 Jul 1:S0085-2538(24)00450-2. doi: 10.1016/j.kint.2024.
    >> Share

    May 2024
  71. CORKEN AL, Ong V, Kore R, Ghanta SN, et al
    Platelets, Inflammation, and Purinergic Receptors in Chronic Kidney Disease.
    Kidney Int. 2024 May 29:S0085-2538(24)00381-8. doi: 10.1016/j.kint.2024.
    >> Share

  72. CHAN GC, Kalantar-Zadeh K, Ng JK, Tian N, et al
    Frailty in Patients on Dialysis.
    Kidney Int. 2024 May 3:S0085-2538(24)00315-6. doi: 10.1016/j.kint.2024.
    >> Share

  73. GOLDSTEIN CE, Taljaard M, Nicholls SG, Beaucage M, et al
    The Ottawa Statement implementation guidance document for cluster randomized trials in the hemodialysis setting.
    Kidney Int. 2024;105:898-911.
    >> Share

  74. CULLIS B, McCulloch M, Finkelstein FO
    Development of PD in lower-income countries: a rational solution for the management of AKI and ESKD.
    Kidney Int. 2024;105:953-959.
    >> Share

    April 2024
  75. WONG G, Bernier-Jean A, Rovin B, Ronco P, et al
    Time for Action: Recognising chronic kidney disease as a major non-communicable disease driver of premature mortality.
    Kidney Int. 2024 Apr 2:S0085-2538(24)00247-3. doi: 10.1016/j.kint.2024.
    >> Share


  76. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
    Kidney Int. 2024;105.
    >> Share

  77. LEVIN A, Ahmed SB, Carrero JJ, Foster B, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
    Kidney Int. 2024;105:684-701.
    >> Share

    March 2024
  78. WINKELMAYER WC, Lensing AWA, Thadhani RI, Mahaffey KW, et al
    A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
    Kidney Int. 2024 Mar 25:S0085-2538(24)00196-0. doi: 10.1016/j.kint.2024.
    >> Share

  79. PIETERS TT, Besseling PJ, Bovee DM, Rookmaaker MB, et al
    Discrepancies between transcutaneous and estimated glomerular filtration rates in rats with chronic kidney disease.
    Kidney Int. 2024 Mar 19:S0085-2538(24)00187-X. doi: 10.1016/j.kint.2024.
    >> Share

  80. GILL JS, Chadban SJ
    Pretransplant screening for coronary artery disease: data are required before practice change.
    Kidney Int. 2024;105:470-472.
    >> Share

    February 2024
  81. LEE J, Lee J, Kim K, Lee J, et al
    Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition.
    Kidney Int. 2024 Feb 29:S0085-2538(24)00163-7. doi: 10.1016/j.kint.2024.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016